Substance / Medication

Daclatasvir

Overview

Active Ingredient
daclatasvir
RxNorm CUI
1606218

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

9 trials linked to this intervention

9
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials.
Chen Chao-Kun, Weng Teng-Song, Chen Yu-Hung et al. · Expert Rev Clin Pharmacol · 2022
PMID: 35852099Meta-Analysis
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment.
Zein Ahmad Fariz Malvi Zamzam, Sulistiyana Catur Setiya, Raffaello Wilson Matthew et al. · Postgrad Med J · 2022
PMID: 37066509Meta-Analysis
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
Simmons Bryony, Wentzel Hannah, Mobarak Sara et al. · J Antimicrob Chemother · 2021
PMID: 33063117Meta-AnalysisFull text (PMC)
Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
Ahmed Ali Mahmoud, Doheim Mohamed Fahmy, Mattar Omar Mohamed et al. · J Med Virol · 2018
PMID: 28892235Meta-Analysis
Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.
Wang Hui-Lian, Lu Xi, Yang Xudong et al. · J Gastroenterol Hepatol · 2017
PMID: 27597318Meta-Analysis
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
Liao Haotian, Tan Ping, Zhu Zexin et al. · Clin Res Hepatol Gastroenterol · 2017
PMID: 28082137Meta-Analysis
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Sokhela Simiso, Bosch Bronwyn, Hill Andrew et al. · J Antimicrob Chemother · 2022
PMID: 35953881RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Daclatasvir (substance)
SNOMED CT
712519008
UMLS CUI
C3252090
RxNorm CUI
1606218

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
9
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.